CJC-1295 vs Follistatin 344

CJC-1295 and Follistatin 344 represent divergent approaches to modulating body composition at the molecular level. CJC-1295 acts upstream by stimulating the release of growth hormone (GH) and insulin-like growth factor 1 (IGF-1) through its role as a GHRH analogue. In contrast, Follistatin 344 directly inhibits myostatin, a negative regulator of muscle growth, thereby promoting hypertrophy without altering systemic GH levels. This comparison explores their mechanisms, clinical evidence, dosing protocols, and safety profiles to guide researchers in selecting the appropriate peptide for their experimental objectives.

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH), originally developed by ConjuChem Technologies for HIV-associated lipodystrophy. It exists in two formulations: with Drug Affinity Complex (DAC) for extended half-life (5.8–8.1 days) and without DAC (Mod GRF 1-29) for shorter, pulsatile release (half-life ~30 minutes). Two randomized, double-blind, placebo-controlled clinical trials from 2006 (Teichman et al.) demonstrated dose-dependent GH increases of 2- to 10-fold and IGF-1 elevations of 1.5- to 3-fold in healthy adults aged 21–61. The non-DAC version is often considered safer due to its more physiological pulsatile GH release pattern, which may reduce risks of receptor desensitization. Research also suggests CJC-1295 may improve body composition and promote deep sleep, though these effects require further validation.

Follistatin 344 is a naturally occurring glycoprotein (344 amino acids) that binds and neutralizes activin and myostatin, two TGF-β superfamily members that inhibit muscle growth. By blocking myostatin, follistatin allows greater muscle hypertrophy. Gene therapy approaches using follistatin (AAV1-FS344) have been tested in human clinical trials for Becker muscular dystrophy and inclusion body myositis. The recombinant protein version sold by research vendors has extremely limited human data.

Key claims: Increases muscle mass by blocking myostatin; Enhances strength and physical performance.

Both CJC-1295 and Follistatin 344 are investigated for their potential to modulate body composition, particularly in contexts of muscle growth and metabolic health. CJC-1295 is also studied in anti-aging research due to its ability to elevate GH and IGF-1 levels, which decline with age. Follistatin 344, by contrast, has not been linked to additional unique applications beyond its role in myostatin inhibition and muscle hypertrophy. Researchers should note that while both peptides target body composition, their mechanisms are distinct: CJC-1295 acts systemically via the GH/IGF-1 axis, whereas follistatin operates locally at the muscle tissue level.

For CJC-1295, common side effects include transient flushing or a 'head rush' within 5–10 minutes post-injection, which is considered a hallmark of a potent injection and is generally harmless. Self-reported effects include flu-like symptoms, headaches, irritability, anxiety, nausea, and mild hives. Water retention and edema are dose-dependent, resulting from GH-induced sodium and water retention via the kidneys. For Follistatin 344, gene therapy trials have shown it to be generally well-tolerated, with mild injection site reactions and one case of transient liver enzyme elevation. The recombinant protein form lacks human safety data, and theoretical concerns exist regarding reproductive effects, as follistatin regulates follicle-stimulating hormone (FSH). Researchers should weigh these profiles when designing studies.